Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Global Healthcare Conference on June 8, 2026. These events will be webcast and accessible on the company's website. Rhythm focuses on rare neuroendocrine diseases with its lead drug, IMCIVREE (setmelanotide), approved for treating specific genetic obesity disorders. The presentations aim to update investors on company progress and clinical developments.
Pepeto's presale is rapidly advancing, attracting significant attention as its exchange and cross-chain bridge near completion. The project uses secure lock and mint technology to enable token swaps across Ethereum, BNB Chain, and Solana, promising z...
Biogen has agreed to acquire RayThera Inc. for up to $1 billion, including upfront and milestone payments. This acquisition adds multiple anti-inflammatory drug candidates to Biogen's immunology portfolio, with the lead asset expected to enter Phase ...
Investar Holding Corporation declared a quarterly cash dividend of $0.12 per share for its common stock, payable on July 31, 2026, to shareholders of record as of June 30, 2026. This dividend represents a 9% increase from the previous quarter and mar...
Trinity Capital Inc. announced a monthly dividend of $0.17 per share for July, August, and September 2026, continuing its streak of consistent or increased dividends for over six years. The dividends are paid from taxable earnings and may include ret...
Apple CEO Tim Cook announced that the company will raise prices across its product lineup due to unprecedented increases in memory and storage chip costs. The surge is driven by a major reallocation of DRAM and NAND supply toward AI infrastructure, c...
